10x Genomics (TXG) Cash from Investing Activities (2018 - 2026)

10x Genomics has disclosed Cash from Investing Activities across 9 years of filings, most recently posting -$7.7 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 723.75% year-over-year to -$7.7 million; the TTM figure through Jun 2026 stood at -$19.7 million (up 66.14% YoY), while the FY2025 annual figure was -$13.4 million, up 58.82% from the prior year.
• Cash from Investing Activities came in at -$7.7 million for Q2 2026 at 10x Genomics, down from -$1.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $120.0 million in Q1 2023 to a low of -$257.6 million in Q1 2022.
• Average Cash from Investing Activities over 5 years is -$15.1 million, with a median of -$2.8 million recorded in 2024.
• Year-over-year, Cash from Investing Activities jumped 367.75% in 2024 and slumped 723.75% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$33.2 million in 2022, then jumped by 139.49% to $13.1 million in 2023, then tumbled by 493.89% to -$51.6 million in 2024, then soared by 96.5% to -$1.8 million in 2025, then slumped by 328.53% to -$7.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$7.7 million in Q2 2026, -$1.3 million in Q1 2026, and -$1.8 million in Q4 2025.